Cargando…
Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
Direct oral anticoagulants (DOAC) are currently the drug of choice for drug prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). However, repeated ischemic stroke or systemic embolism and bleeding while on DOAC is still a challenging clinical phenomenon in the managem...
Autores principales: | Samoš, Matej, Bolek, Tomáš, Stančiaková, Lucia, Péč, Martin Jozef, Brisudová, Kristína, Škorňová, Ingrid, Staško, Ján, Mokáň, Marián, Kubisz, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655219/ https://www.ncbi.nlm.nih.gov/pubmed/36362597 http://dx.doi.org/10.3390/jcm11216369 |
Ejemplares similares
-
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
por: Prídavková, Dana, et al.
Publicado: (2019) -
Does atorvastatin therapy change the anti‐Xa activity in xabans‐treated patients with atrial fibrillation?
por: Škorňová, Ingrid, et al.
Publicado: (2021) -
Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?
por: Blaško, Peter, et al.
Publicado: (2022) -
COVID-19 and the Response to Antiplatelet Therapy
por: Bolek, Tomáš, et al.
Publicado: (2023) -
Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases
por: Samoš, Matej, et al.
Publicado: (2021)